Supplementary Table S1 from Clinical Benefit of Avapritinib in KIT-Mutant Gastrointestinal Stromal Tumors: A Post Hoc Analysis of the Phase I NAVIGATOR and Phase I/II CS3007–001 Studies
Year: 2024
Type: supplementary-materials
Abstract: Supplementary Table S1. Baseline demographics and disease characteristics of patients with GIST harboring only KIT mutations treated with avapritinib 300 mg QD in the phase I NAVIGATOR study (n = 131) and phase I/II CS3007-101 China bridging trial (n = 29), according to study analysis population.
Language: English
Subfield: Gastroenterology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4391882012